Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
IFNLR1 Biologics Sequence Review Report 2026: Interferon lambda receptor 1 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of IFNLR1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
IFNGR2 Biologics Sequence Review Report 2026: Interferon gamma receptor 2 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of IFNGR2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
IFNGR1 Biologics Sequence Review Report 2026: Interferon gamma receptor 1 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of IFNGR1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
IFNAR2 Biologics Sequence Review Report 2026: Interferon alpha/beta receptor 2 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of IFNAR2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
IFNAR1 Biologics Sequence Review Report 2026: Interferon alpha/beta receptor 1 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of IFNAR1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
ICAM4 Biologics Sequence Review Report 2026: Intercellular adhesion molecule 4 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of ICAM4 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
ICAM3 Biologics Sequence Review Report 2026: Intercellular adhesion molecule 3 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of ICAM3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
8 min read
ICAM2 Biologics Sequence Review Report 2026: Intercellular adhesion molecule 2 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of ICAM2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
8 min read
ICAM1 Biologics Sequence Review Report 2026: Intercellular adhesion molecule 1 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of ICAM1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
HLA-DQA1 Biologics Sequence Review Report 2026: HLA class II histocompatibility antigen, DQ alpha 1 chain Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of HLA-DQA1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
HLA-DPB1 Biologics Sequence Review Report 2026: HLA class II histocompatibility antigen, DP beta 1 chain Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of HLA-DPB1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
HLA-DPA1 Biologics Sequence Review Report 2026: HLA class II histocompatibility antigen, DP alpha 1 chain Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of HLA-DPA1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
<
1
<<
252
253
254
255
256
>>
1670
>